Novel Adenylyl Cyclase 1 Inhibitors for Chronic Pain and Opioid Dependence

Back to all technologies
Download as PDF
2017-WATT-67991
The annual cost of chronic pain in the United States is estimated to be $635 million, impacting more than 100 million people, as reported by the American Pain Society. The Centers for Disease Control and Prevention estimate that 91 people die in the U.S. every day from an opioid overdose. Chronic and inflammatory pain are commonly treated with opioids. However, use of opioids often leads to opioid dependence. Dependence puts patients at risk for overdose, both fatal and nonfatal. As the World Health Organization states, 45% of drug users experience nonfatal overdose.

Researchers at Purdue University are developing compounds to provide effective pain relief without the risks associated with opioids. The researchers' compounds selectively inhibit adenylyl cyclase 1, an enzyme that has previously been validated as a target for inflammatory pain. Inhibiting adenylyl cyclase 1 produces an analgesic effect in animal models. These compounds also show promise as a therapy to treat opioid dependence, itself.

Advantages:
-Chronic and inflammatory pain relief
-Non-opioid
-Non-addictive

Potential Applications:
-Pain treatment
-Opioid dependence treatment option
Jul 18, 2018
Utility Patent
United States
10,662,176
May 26, 2020

Apr 3, 2020
DIV-Gov. Funding
United States
(None)
(None)

Jul 18, 2017
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org